Skip to main content
. 2021 Mar 2;9(3):e001901. doi: 10.1136/jitc-2020-001901

Figure 2.

Figure 2

Ongoing prospective clinical trials to determine criteria for early discontinuation of immune checkpoint inhibitors. CR, complete response; MTR, maximal tumor response; PR, partial response; SD, stable disease.